Why is Astrazeneca Phar falling/rising?

As of 15-Jul, Astrazeneca Pharma India Ltd is currently priced at 9,178.85, reflecting a slight increase of 7.45 (0.08%). Today's performance indicates that the stock underperformed its sector by 1.17%, despite reaching an intraday high of Rs 9649.6, which represents a 5.21% increase. Over the past week, the stock has shown a modest gain of 0.43%, while it has experienced a significant decline of 12.79% over the past month. The company has demonstrated strong financial performance, with a net profit growth of 88.82% and positive results in the last two quarters. However, concerns about long-term growth persist due to a relatively low annual operating profit growth rate of 15.95% over the last five years and a high valuation indicated by a Price to Book Value of 32.2.
Broader market context shows that while Astrazeneca has outperformed the benchmark Sensex over the long term, with a year-to-date return of 25.14% compared to the Sensex's 5.67%, it has struggled in the short term. The Sensex has declined by 1.36% over the past week, contrasting with Astrazeneca's slight gain. Additionally, the stock's liquidity appears adequate for trading, but there is a notable decrease in institutional investor participation, which may signal caution among more experienced investors. This combination of strong historical performance and current investor sentiment may contribute to the stock's recent price movements.